Key Points {#d30e286}
==========

Renal cell carcinoma (RCC) cells differ with respect to programmed death ligand (PD-L1) regulation by interferon γ (IFN-γ)-signaling.In ccRCC cells, intact IFN-γ signaling can induce PD-L1. In pRCC, PD-L1 is refractory towards IFN-γ-pathway signaling.In tumors with predominantly intact IFN-γ signaling such as ccRCC and melanoma, high *PD-L1-*mRNA levels are associated with prolonged survival of patients; this association is not observed in pRCC patients.

Introduction {#Sec1}
============

Signaling between programmed death (PD-1) and PD-1 ligands (PD-L1 alias CD274; PD-L2 alias CD273 or PDCD1LG2) regulates immune-editing of cancer cells and can be exploited therapeutically as a target for immune checkpoint blockade \[[@CR1], [@CR2]\]. Binding between PD-L1 on cancer cells or antigen-presenting cells and PD-1 expressed on T cells elicits co-inhibitory signals. These signals suppress anti-cancer immune responses that involve major histocompatibility complex (MHC) and T-cell receptor (TCR) interactions in the tumor microenvironment \[[@CR3]\].

The co-inhibitory signaling pathway can be blocked by intravenous infusion of antibodies against PD-L1 or PD-1 \[[@CR4]\]. A considerable percentage of patients in a growing number of malignancies can benefit from this therapy \[[@CR5]\]. Renal cell carcinoma (RCC) is resistant to cytotoxic chemotherapy and traditionally less responsive to conventional radiation treatments. In advanced RCC, PD-1/PD-L1-based immune checkpoint blockade therapy was initially approved as second-line monotherapy after anti-angiogenic therapy with tyrosine kinase inhibitors (TKIs). Meanwhile, first-line combination therapies with nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA-4 antibody), as well as pembrolizumab (anti-PD-1 antibody) or avelumab (anti-PD-L1) each combined with axitinib (TKI) are approved \[[@CR6]--[@CR9]\].

Biomarkers predicting disease outcome and therapy response towards immune checkpoint blockade are highly sought after to avoid treating patients who are unlikely to benefit from this therapy and, thus, will be unnecessarily exposed to immune-related adverse events \[[@CR10]\]. Potential markers are PD-L1 expression, infiltration of tumor tissue by immune cells, and tumor mutational burden indicating the abundance of tumor neoantigens \[[@CR11]\].

Interferon-γ (IFN-γ) released from immune cells such as T cells, NK cells, and macrophages can induce PD-L1 in adjacent tumor cells via IFN-γ-receptor (IFN-γR) signaling \[[@CR12]\]. IFN-γ/IFN-γR signaling triggers tyrosine phosphorylation of Janus kinases (JAK1/2), which targets further downstream signal transducer and activators of transcription (STAT1) and subsequently interferon regulatory factor (IRF1), thereby inducing various target genes, among them PD-L1 and chemokine CXCL10 \[[@CR13], [@CR14]\]. IFN-γ has both tumorigenic and immunogenic properties in the tumor microenvironment. In particular, IFN-γ promotes T-cell chemotaxis via the induction of inflammatory chemokines. Conversely, IFN-γ released from T cells attenuates immune responses through induction of *PD-L1-*mRNA/PD-L1 protein on tumor cells. Therefore, we speculate that in tumors such as ccRCC, where PD-Ll is not constitutively driven by oncoviruses (such as EBV), oncogenes (such as ras), or AKT \[[@CR15]\], the tissue level of *PD-L1-*mRNA may indicate T-cell responsiveness of these tumors. Since PD-L1 level is under the control of several post-transcriptional mechanisms \[[@CR16]\], distinguishing between *PD-L1-*mRNA and PD-L1 protein is critical.

Here, we studied the regulation of *PD-L1-*mRNA and PD-L1 protein by IFN-γ in clear-cell RCC (ccRCC) and papillary RCC (pRCC) cell lines. Additionally, we performed gene expression and IFN-γ-signaling analysis of *PD-L1-*mRNA in tumor tissues with corresponding survival data from patients with ccRCC, pRCC, and skin cutaneous melanoma (SKCM).

Material and Methods {#Sec2}
====================

Cell Culture, RNA, and Protein Preparation {#Sec3}
------------------------------------------

Renal cancer cell lines CaKi-1, CaKi-2, Cal-54, and A-498 were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum, 1% stable glutamine, and 1% penicillin/streptomycin solutions (PAA Laboratories, Pasching, Austria) at 37 °C with 5% CO~2~ in humidified air \[[@CR17]\]. Sub-confluent cells were treated with IFN-γ (10 ng/mL from R&D Systems, Minneapolis, MN, USA) for 24 h. RNA extraction was performed with Trifast (Peqlab, Erlangen, Germany) according to the manufacturers' protocol. Protein extraction was performed with RIPA buffer (Cell Signalling Technology Europe, Frankfurt a.M., Germany) supplemented with protease inhibitor cocktail (Sigma-Aldrich Chemie, Munich, Germany) and phosphatase blocker (Phos-STOP, Roche Diagnostics, Mannheim, Germany). Extraction procedure was according to the manufacturers' protocols. The cell lines were from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany, and were recently authenticated using DNA profiling with highly polymorphic short-tandem repeats (STR) loci. All experiments were performed with tested mycoplasma-free cells (Minerva Biolabs GmbH, Berlin, Germany) and analyses were performed three times.

Characterization of Renal Cell Carcinoma (RCC) Cell Lines {#Sec4}
---------------------------------------------------------

A recent study explored the genomic similarity of common RCC cell lines and RCC tumor samples including CaKi-1, CaKi-2, A-498, and Cal-54 cell lines \[[@CR18]\]. Expression-based classification of ccRCC cell lines assigned CaKi-1 and A-498 cell lines to the aggressive ccRCC subtype and excluded CaKi-2 cell line as ccRCC. Based on further studies, CaKi-2 cell line resembled pRCC, since this cell line harbored typical high-expression levels of MET and LRRK2 \[[@CR19]\] as well as chromosome 8 aberrations and MYC activation \[[@CR20]\]. Cytological and histologic analysis of CaKi-2 cells in orthotopic and sub-cutaneous mouse models demonstrated typical papillary characteristics \[[@CR21], [@CR22]\]. Assignment of Cal-54 cells to either of these subtypes is less certain. The CAL-54 cell line conforms with copy number amplifications (CNAs) in several key kidney cancer genes. CNA-based cluster analysis showed characteristic pRCC alterations \[[@CR18]\].

Quantitative Real-Time RT-PCR {#Sec5}
-----------------------------

RNA (1 µg) from cell lines was used as a template for cDNA synthesis after digestion of genomic DNA with RNase-free DNase (RevertAid First Strand cDNA synthesis Kit, Fermentas Life Science, St. Leon-Rot, Germany). Real-time RT-PCR was performed with SYBR Green Fluorescein Mix (ABgene UK, Epsom, UK). Cycling conditions were 95 °C for 15 min, followed by 45 cycles of 95 °C for 15 s, 60 °C for 15 s, and 72 °C for 30 s. Relative levels of mRNA are displayed as delta cycle threshold (∆Ct) values (log-2-scale) with the mean of TATA-binding protein (TBP) as reference mRNA. The primer sets were synthesized commercially (Biomers, Ulm, Germany). The gene sequences of forward (+) and reverse primer (−) are listed in Table S1.

Western Blot {#Sec6}
------------

Protein samples (40 µg, determined by Pierce BCA Protein Assay (ThermoFisher, Scientific, Darmstadt, Germany)) were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis (gradient gel 4--20%) and transferred to nitrocellulose membranes by electro-blotting (Bio-Rad, Munich, Germany). The membranes were blocked at room temperature for 1.5 h in TRIS-buffered saline with 0.1% Tween containing 5% dry milk, and then the primary antibodies were added and incubated at 4 °C for 24--48 h. The antibodies were as follows: PD-L1 \#13684, PD-L2 \#82723, STAT1 \#9172, JAK1 \#3344, phospho-JAK1 \#74129, IRF1 \#8478, JAK2 \#3230, phospho-JAK2 \#3771; host rabbit (Cell Signalling Technology Europe, Frankfurt a.M., Germany); β-actin (\#MAK6019); host mouse (Linaris, Dossenheim, Germany). Then, secondary antibodies against rabbit (Linaris) or mouse (Thermo Fisher) coupled with horseradish peroxidase were added for band detection with enhanced chemiluminescent luciferase kit (Thermo Scientific, Rockford, IL, USA) by an imager system (Fluorchem IS-8900, Alpha Innotech, San Leandro, CA, USA).

Patients, Datasets, and Statistical Analysis {#Sec7}
--------------------------------------------

The cBioPortal for Cancer Genomics provided gene expression data obtained by RNA-Seq from Kidney Renal Clear Cell Carcinoma (ccRCC; TCGA Provisional), Kidney Renal Papillary Cell Carcinoma (pRCC; TCGA Provisional), and Skin Cutaneous Melanoma (SKCM; TCGA Provisional) with matching clinical patients' data (v2.2.1; <https://www.cbioportal.org/>) \[[@CR23], [@CR24]\]. Co-expression analysis of PD-L1 was performed by online software from cBioPortal (Supplementary Tables S2--S4). Selected *r* values were analyzed by one-way ANOVA with subsequent Dunn's multiple comparisons test (Table [1](#Tab1){ref-type="table"}) employing Graphpad Prism Version 7.04. For survival analysis, data of patients with SKCM, ccRCC, and pRCC were sorted according to median *PD-L1-*mRNA levels employing MS-Office Excel. The comparison of survival curves is indicated by hazard ratios (Mantel--Haenszel) and significant differences were determined by the Log-rank (Mantel-Cox) test. The clinicopathological parameters of patients in relation to *PD-L1*-mRNA levels are given in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}. Information about the type of therapy includes whether neoadjuvant and adjuvant treatment has been carried out or not. Specific information about systemic therapy was not available. Significant differences of the clinicopathological parameters between low and high *PD-L1*-mRNA level groups were analyzed by the Chi-square test (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}).Table 1Ranking of the top PD-L1-mRNA correlates with members related to the IFN-γ pathway in tissues from SKCM, ccRCC, and pRCCCorrelateSKCMccRCCpRCC*r* valuerank \#*q* value*r* valuerank \#*q* value*r* valuerank \#*q* valueSTAT10.80711.49E-1050.466956.64E-280.3958617.98E-11IFNG0.74681.20E-810.24122308.07E-080.18745223.88E-03IRF10.732163.25E-770.26318803.77E-090.03095686.92E-01CXCL100.731177.64E-770.4252314.96E-230.36611732.26E-09JAK20.6242551.72E-500.56724.55E-430.4394732.63E-13Total 20,164Total 20,180Total 20,139One-way ANOVA (three groups) Kruskal--Wallis test: *p *= 0.0009\*\*\*Follow-up: Dunn\'s multiple comparisons test SKCM vs. ccRCC: *p* = 0.071; SKCM vs. pRCC: *p* = 0.007\*\*; ccRCC vs. pRCC, *p* \> 0.9999*r value* Spearman value, *q value* multiple corrected significance, *rank* position relative to all correlated RNA-seq genes, total gene numberTable 2SKCM TCGA patient data: clinicopathological parameters in relation to PD-L1 mRNA level expressionVariableAll cases (*n*)Low-PD-L1 (*n*)High PD-L1 (*n*)*p* valueAge (years) \< 5822010648.2%11451.8%0.511 ≥ 5824012351.3%11748.8% Sum460229231Gender Female1758045.7%9554.3%0.172 Male28514952.3%13647.7% Sum460229231Race category White43721449%22351%0.287 Non-White13969.2%430.8% NA10660%440% Sum460229231Tumor stage 06350%350%0.081 I773342.9%4457.1% II1408460%5640% III1698147.9%8852.1% IV221045.5%1254.5% NA461839.1%2860.9% Sum460229231Lymph node n023012152.6%10947.4%0.866 n1733345.2%4054.8% n2492244.9%2755.1% n3542750%2750% Nx351748.6%1851.4% NA19947.4%1052.6% Sum460229231Metastasis m041120549.9%20650.1%0.764 m1231043.5%1356.5% NA261453.8%1246.2% Sum460229231Clark level I5360%240%0.069 II18633.3%1266.7% III763242.1%4457.9% IV1678651.5%8148.5% V513466.7%1733.3% NA1436847.6%7552.4% Sum460229231Neoadjuvant treatment0.523 No43521549.4%22050.6% Yes251456%1144% Sum460229231Adjuvant treatment No42821249.5%21650.5%0.912 Yes231252.2%1147.8% NA9555.6%444.4% Sum460229231*NA* not available^a^Chi-square test^b^Median ageTable 3ccRCC TCGA patient data: clinicopathological parameters in relation to PD-L1 mRNA levelVariableAll cases (*n*)Low-PD-L1 (*n*)High PD-L1 (*n*)*p* valueAge (years) \< 6126412647.7%13852.3%0.279 ≥ 6126914152.4%12847.6% Sum533267266Gender Female1888143.1%10756.9%*0.017* Male34518653.9%15946.1% Sum533267266Race category White46223250.2%23049.8%0.508 Non-White643351.6%3148.4% NA7228.6%571.4% Sum533267266Tumor stage I26713851.7%12948.3%0.102 II571933.3%3866.7% III1236653.7%5746.3% IV834351.8%4048.2% NA3133.3%266.7% Sum533267266Lymph node n024011146.3%12953.8%0.267 n116956.3%743.8% Nx27714753.1%13046.9% Sum533267266Metastasis m0221150%1150%0.167 m133100%00% Mx8675%225% NA50024749.4%25350.6% Sum533267266Grading g114642.9%857.1%0.706 g222910746.7%12253.3% g320611053.4%9646.6% g4764052.6%3647.4% Gx5240%360% NA3266.7%133.3% Sum533267266Neoadjuvant treatment No51626150.6%25549.4%0.215 Yes17635.3%1164.7% Sum533267266Adjuvant treatment No312064.5%1135.5%0.098 NA50224749.2%25550.8% Sum533267266*NA* not available^a^Chi-square test^b^Median ageTable 4pRCC TCGA patient data: clinicopathological parameters in relation to PD-L1 mRNA levelVariableAll cases (*n*)Low-PD-L1 (*n*)High PD-L1 (*n*)*p* value^a^Age (years)^b^ \< 611356749.6%6850.4%0.950 ≥ 611527650%7650% NA2 Sum287143144Gender Female762735.5%4964.5%*0.003* Male21311855.4%9544.6% Sum289145144Race category White20610852.4%9847.6%0.130 Non-White692840.6%4159.4% NA14964.3%535.7% Sum289145144Tumor stage I1719052.6%8147.4%0.467 II211152.4%1047.6% III522140.4%3159.6% IV15640%960% NA301756.7%1343.3% Sum289145144Lymph node n0502550%2550%0.388 n124833.3%1666.7% n24250%250% Nx21011052.4%10047.6% NA100%1100% Sum289145144Metastasis m0954143.2%5456.8%0.089 m19222.2%777.8% Mx1709455.3%7644.7% NA15853.3%746.7% Sum289145144Neoadjuvant treatment(\*) No28914550.2%14449.8% Yes000 Sum289145144Adjuvant treatment No1589258.2%6641.8% Yes11100%00% NA1305240%7860%(\*\*) Sum289145144*NA* not available\*Not applicable\*\*Difference in NA ratio \> 2^a^Chi-square test^b^Median age

Gene Set Enrichment Analysis (GSEA) {#Sec8}
-----------------------------------

Analyses of RNA-Seq data of SKCM, ccRCC, and pRCC were conducted with GSEA v4.0.3 for Windows (Joint project of University of California San Diego and Broad Institute: <https://www.gsea-msigdb.org/gsea/index.jsp>) \[[@CR25], [@CR26]\]. We tested two gene sets by GSEA. The first gene set (*gs-ifng-sig-table1*) corresponds to the five correlates of *PD-L1-*mRNA displayed in Table [1](#Tab1){ref-type="table"}. The second gene set (*geneset-ifng-m14004)* was downloaded from Molecular Signatures Database (MSigDB) v7.1 and comprises 88 genes (Table S5). The statistical values of GSEA are explained in the legend to Fig. [2](#Fig2){ref-type="fig"}.

Results {#Sec9}
=======

Regulation of PD-L1 in RCC Cells {#Sec10}
--------------------------------

Initially, we scanned PD-L1, PD-L2, and critical mediators of IFN-γ signaling in two ccRCC cell lines (CaKi-1, A-498), one undefined RCC cell line Cal-54, and one pRCC cell line (CaKi-2). Transcripts of *PD-L1*, *PD-L2*, *IFN-γR1*, *IFN-γR2*, *IRF1*, *STAT1*, *JAK1*, and *JAK2* were detected (Fig. [1](#Fig1){ref-type="fig"}a), with the exception of *PD-L2-*mRNA, which was not detectable in CaKi-2 cells. *PD-L1*, *PD-L2, JAK2*, *STAT1*, and *IRF1* mRNAs were induced by IFN-γ in CaKi-1, A498, and Cal-54 cells but not in CaKi-2 cells. Regulation of *PD-L1-*mRNA was congruent with the regulation of *CXCL10*-mRNA, a typical chemokine target gene of IFN-γ.Fig. 1Regulation of PD-L1 and components of the IFN-γ-signalling cascade in ccRCC cell lines (CaKi-1, A-498), pRCC cell line (CaKi-2) and Cal-54 RCC cell line. **a** Levels of mRNA (∆Ct) for *PD-L1, PD-L2, CXCL10, JAK2, STAT1, IRF1, JAK1, IFN-γR1, IFN-γR2* in control cells (−con) and cells treated with IFN-γ (10 ng/ml) for 24 h (+IFN-γ) are shown. Transcripts that were not inducible by IFN-γ in CaKi-2 cells, in contrast to the other cell lines, are gray-shaded. Box plots indicate means with error bars corresponding to minimum and maximum values (*n* = 3). **b** Western-blot analysis of control cells (con) or cells treated with IFN-γ (10 ng/ml) for 24 h with antibodies for PD-L1, p-JAK2, JAK2, p-JAK1, JAK1, IRF1, and cytoplasmic β-actin. The molecular weights are: PD-L1, \~ 50kd; PD-L2, \~ 50 kd; phosphate (P)-JAK2, 125 kd; JAK2, \~ 125 kd; phosphate (P)-JAK1, 130 kd; JAK1, \~ 130 kd; IRF1, \~ 48 kd; STAT1, \~ 90 kd; β-actin, \~ 43kd. **c** Schematic diagram of analyzed components of the IFN-γ-signaling cascade. *nd* below detection level, *IFNG* IFN-γ, *Y* tyrosine residue

Concordantly, at the protein level (Fig. [1](#Fig1){ref-type="fig"}b) we observed strong PD-L1 induction in CaKi-1, A498, and Cal-54, but not in CaKi-2 cells. PD-L2 was induced by IFN-γ in CaKi-1 and A-498, but not in CaKi-2 and Cal-549 cells. IFN-γ triggered phosphorylation of JAK2 (phospho-JAK2) and JAK1 (phospho-JAK1) as an off--on response in CaKi-1, A-498, and Cal-54 cells. In CaKi-2 cells, phospho-JAK2/JAK1 was not detectable at all. The non-phosphorylated form of JAK1 was unchanged in CaKi-1 and Cal-54 cells, not detectable in CaKi-2 cells, and induced in A-498 cells. The non-phosphorylated form of JAK2 appeared only slightly induced in the IFN-γ-responsive cells. The transcription factor IRF1 was only induced by IFN-γ in IFN-γ-responsive CaKi-1, A-498, and Cal-54 cells, but not in CaKi-2 cells. Critical components of the IFN-γ-signaling cascade are illustrated in Fig. [1](#Fig1){ref-type="fig"}c.

Co-Expression Analysis of PD-L1-mRNA with RNA-Seq Data from SKCM, ccRCC, and pRCC tissues {#Sec11}
-----------------------------------------------------------------------------------------

Next, we performed co-expression analysis of *PD-L1-*mRNA (obtained from RNA-Seq data) against all detectable mRNAs in the RNA-Seq-data sets from ccRCC, pRCC, and SKCM tissues, respectively. Correlates from the IFN-γ-signaling cascade (STAT1, IFN-γ, IRF1, JAK2) including CXCL10 with correlation values (*r* \> 0.5) in SKCM tissue are displayed in Table [1](#Tab1){ref-type="table"}. Their correlation values were also determined in ccRCC and pRCC tissue. ANOVA analysis revealed significant differences between SKCM, ccRCC, and pRCC values (*p* \< 0.01). A subsequently performed multiple comparison test determined a significant difference between SKCM and pRCC tissues (*p* \< 0.01). The *r* values for JAK1 were lower than 0.5 (SKCM *r* = 0.361, ccRCC *r* = 0.242, and pRCC *r* = 0.328) and are displayed together with the entire correlation data sets in Tables S2--S4.

Gene-Set Enrichment Analysis (GSEA) for the IFN-γ-Pathway from SKCM, ccRCC, and pRCC Tissues in Relation to High and Low PD-L1-mRNA Levels {#Sec12}
------------------------------------------------------------------------------------------------------------------------------------------

Since PD-L1 regulation appeared heterogeneously connected to the IFN-γ pathway in SKCM, ccRCC, and pRCC, we performed gene-set enrichment analysis (GSEA) of the RNA-Seq data sets for the IFN-γ-pathway. The GSEA is a test to determine if a gene set (e.g., derived from the IFN-γ-pathway) may have an association with a biological category (e.g., high and low PD-L1 expression level). Here, we tested two gene sets for the IFN-γ-pathway. The first gene set termed gs-ifng-sig-table1 comprises the five PD-L1-mRNA correlates from Table [1](#Tab1){ref-type="table"}. The second gene set, named gs-ifng-m14004, comprises 88 genes (Supplementary Table S5). The GSEA plots for both gene sets document that the IFN-γ-pathway was activated in cases with high *PD-L1*-mRNA levels in SKCM and ccRCC tissues but not in pRCC tissues. Both gene sets yielded similar results. The more comprehensive gene set (*gs-ifng-m14004*) had the highest enrichment score (ES) in SKCM tissues (ES = 0.825, FDR, *q* value 0.0; FWER *p* value 0.0) (Fig. [2](#Fig2){ref-type="fig"}a, right panel) followed by ccRCC tissues (ES = 0.542, FDR, *q* value 0.0603; FWER *p* value 0.031) (Fig. [2](#Fig2){ref-type="fig"}b, right panel). In pRCC tissues, a negative ES value was calculated that did not reach significance (ES = − 0.0404, FDR, *q* value 0.243; FWER *p* value 0.119) (Fig. [2](#Fig2){ref-type="fig"}c, right panel). The corresponding values of gene set *gs-ifng-sig-*table1 were: SKCM tissues (ES = 0.966, FDR, *q* value 0.008; FWER *p* value 0.004) (Fig. [2](#Fig2){ref-type="fig"}a, left panel) followed by ccRCC tissues (ES = 0.918, FDR, *q* value 0.0059; FWER *p* value 0.003) (Fig. [2](#Fig2){ref-type="fig"}b, left panel). In pRCC tissues, a negative ES value was calculated that did not reach significance (ES = -0.684, FDR, *q* value 0.325 FWER *p* value 0.157) (Fig. [2](#Fig2){ref-type="fig"}c, left panel).Fig. 2Gene set enrichment analysis (GSEA) for the IFN-γ pathway in SKCM (**A**), ccRCC (**B**), and pRCC (**C**) tissues. Two gene sets (gs) indicating IFN-γ-signaling were tested. Left panels: *gs-ifng-sig-*table1 with five genes from Table [1](#Tab1){ref-type="table"}. Right panels: *gs-ifng-m14004* with 88 genes from MSigDB. See also description in Sects. 2, and 3, Results. GSEA was performed between dichotomized high- and low-*PD-L1* mRNA level groups based on the respective medians. The enrichment score (ES) was calculated according to the original GSEA statistics \[[@CR26]\]. Significances are based on the false-discovery rate (FDR \< 25%) and indicated by FDR (*q*value) and familywise-error rate (FWER) *p*values in the insets of the GSEA plots

Analogy Between PD-L1-mRNA Regulation in RCC Cell Lines and in RCC Tumor Tissues {#Sec13}
--------------------------------------------------------------------------------

The suggested analogy between *PD-L1*-mRNA regulation in RCC cell lines (Fig. [3](#Fig3){ref-type="fig"}a) and in RCC tumor tissues (Fig. [3](#Fig3){ref-type="fig"}b) is illustrated by correlation graphs of PD-L1 with JAK2, which was selected due to its tightest correlation with IFN-γ signaling in ccRCC (see Table [1](#Tab1){ref-type="table"}). Cells in quadrant Q1 represent those with low *PD-L1*-mRNA levels under basal conditions without IFN-γ (control: CaKi-1-con, Cal-54-con, A-498-con). Cells in Q3 are those with high *PD-L1* levels that were induced by IFN-γ (CaKi-1-IFN-γ, Cal-54-IFN-γ, A-498-IFN-γ). Cells in Q4 mirror RCC cells with relative high *PD-L1-*mRNA levels independent of IFN-γ (CaKi-2-con and CaKi-2-IFN-γ). The tumor tissues of ccRCC were similarly plotted according to their PD-L1/JAK2 score (Fig. [3](#Fig3){ref-type="fig"}b). The observed distribution mirrors that of the cell lines and may be interpreted in analogy to the cell lines, suggesting that in IFN-γ-responsive RCC tissues, *PD-L1/JAK2*-mRNA tissue levels are mainly allocated to either quadrant Q1 or Q3 depending on the IFN-γ abundance in the tumor microenvironment. The virtual arrow with the color gradient from black to red indicates IFN-γ-dependent induction of PD-L1/JAK2 in Q3 (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 3Correlation graph of *PD-L1*-mRNA (y-axes) and *JAK2*-mRNA (x-axes) in RCC cell lines (**a**) and ccRCC tissues (**b**). The samples (z-score values) are allocated in quadrants (Q1--Q4). **a** Q1 reflects IFN-γ-responsive cells (CaKi-1, A-498, Cal-54) under basal culture conditions without IFN-γ (cell name with extension con, black dots), Q3 the same cells after IFN-γ induction (red dots). Q4 contains the pRCC cell line CaKi-2 that is non-responsive to IFN-γ \[CaKi-2 control (black) and IFN-γ-treated cells (red)\]. **b** Allocation of *PD-L1/JAK2* mRNA levels detected in ccRCC tumor tissues. The positioning of the tissues (each represented by a dot) in the quadrants may be similarly interpreted to cell lines. The virtual arrow with the color gradient from black to red suggests IFN-γ-dependent induction of *PD-L1/JAK2-mRNA* in Q3. A perfect positive correlation (*r* = 1) would allocate the dots exclusively on the arrow (crossing Q1 to Q3). In case of less (*r* \< 1) or no correlation (*r* = 0) the dots deviate from the arrow and become distributed over all quadrants (see Table [1](#Tab1){ref-type="table"} for the *r* values of SKCM, ccRCC, and pRCC between *PD-L1-mRNA* with JAK2-mRNA)

Analysis of Patient Survival Data in Relation to PD-L1-mRNA Tumor Tissue Levels {#Sec14}
-------------------------------------------------------------------------------

Next, we tested whether *PD-L1-*mRNA tissue levels have prognostic value and relate to disease outcome as measured by overall survival (OS) and disease-free survival (DFS) (Fig. [4](#Fig4){ref-type="fig"}). Patients were divided according to the median of the tumor tissue levels of *PD-L1*-mRNA from RNA-Seq data in a low (black dotted line) and high PD-L1 group (red, continuous line), respectively. In SKCM with low *PD-L1*-mRNA tissue levels, patient survival was significantly shorter than in those with high-level *PD-L1*-mRNA levels (OS: HR 1.984; *p* \< 0.0001 and DFS: HR 1.436; *p* = 0.0046). In ccRCC, similar differences between high and low *PD-L1*-mRNA were observed (OS: HR 1.571; *p* = 0.0029 and DFS: HR 1.751; *p* = 0.0019). In contrast, in pRCC, no differences in OS and DFS in relation to *PD-L1-*mRNA tissue levels were obvious (OS: HR 0.765; *p* = 0.374 and DFS: HR 0.759; *p* = 0.326).Fig. 4Kaplan--Meier survival curves of overall survival (OS) and disease-free survival (DFS) from patients with SKCM, ccRCC, and pRCC. Patients were divided according to the median of the tumor tissue levels of PD-L1-mRNA from RNA-Seq data in a low- (black dotted line) and high-PD-L1 group (red, continuous line), respectively. Hazard ratio (HR), *p* value (*p*), and the number of patients are indicated. All available RNA seq data and survival data were considered. However, the number of RNA seq data was higher than those of patients' survival and therefore the number within groups can differ

The clinical information of patients with SKCM, ccRCC, and pRCC in relation to low and high *PD-L1*-mRNA groups is listed in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}). Statistical analyses indicated no significant differences between clinicopathological parameters in the respective cohorts, with the exception of a biased gender distribution in ccRCC and pRCC (in ccRCC: 43.1% female in the low *PD-L1*-mRNA group vs. 56.9% female in the high *PD-L1*-mRNA group; *p* \< 0.05; Table [3](#Tab3){ref-type="table"}, and in pRCC: 35.5% female in the low *PD-L1*-mRNA group vs. 64.5% female in the high *PD-L1*-mRNA group; *p* \< 0.05; Table [4](#Tab4){ref-type="table"}).

Discussion {#Sec15}
==========

Here, we demonstrated that RCC subtypes are heterogeneous with regard to IFN-γ signaling and PD-L1 induction. In ccRCC, PD-L1 induction by IFN-γ signaling predominates whereas in pRCC, PD-L1 is apparently non-responsive to IFN-γ signaling. These conclusions are based on cell experiments where PD-L1 was found to be induced by IFN-γ in ccRCC cell lines but not in a pRCC cell line. Further support comes from *PD-L1-*mRNA co-expression analysis and from Gene Set Enrichment analysis (GSEA) performed with RNA-Seq data of tumor tissues. The enrichment score (ES) for IFN-γ-pathway was significantly higher in the high versus the low *PD-L1-*mRNA level group of SKCM tissues. In ccRCC, ES for IFN-γ-pathway was lower but still significant. In pRCC tissue, the ES for IFN-γ-pathway appeared negative without significance. This ranking of *PD-L1* responsiveness towards IFN-γ signaling relates to patient survival when considering low and high *PD-L1*-mRNA tissue levels. In IFN-γ-responsive tumors such as melanoma and ccRCC, patients with high *PD-L1*-mRNA tissue levels had longer OS and DFS than those with low *PD-L1*-mRNA levels. Survival differences between *PD-L1* high and low groups were not detected in pRCC patients. Of note, we did not observe significant differences in the listed clinicopathological parameters in SKCM, ccRCC, and pRCC patients between high- and low-level *PD-L1-*mRNA groups with the exception of gender distribution (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}). Unfortunately, precise information about the kind of systemic adjuvant and neoadjuvant treatments and, particularly, about immune therapy was not available, which represents a limitation of the present study.

Patient-individual differences in IFN-γ responsiveness may causally translate to the observed differences in patient survival dependent on *PD-L1-*mRNA levels. High *PD-L1-*mRNA levels in IFN-γ-responsive tumor cells may indicate an IFN-γ-dependent inflammatory status of the tumor environment that may be less aggressive, reflected in the observed correlation in longer survival. In particular, T cells release IFN-γ upon pMHC recognition in the context of tumor antigen presentation, subsequently raising the *PD-L1*-mRNA transiently from a basal to a high level in IFN-γ-responsive tumor tissues. Thus, high *PD-L1*-mRNA levels may reflect an acute anti-tumor T-cell attack. Therefore, we suggest the *PD-L1-*mRNA tumor tissue level to be a favorable prognostic marker for those tumors that do not constitutively express PD-L1.

Similarly, in bladder cancer, high *PD-L1-*mRNA tissue levels were associated with longer survival in patients who received neither anti-PD-L1 nor anti-PD-1 therapy \[[@CR27]\]. Particularly, high *PD-L1-*mRNA levels were associated with immune cell infiltration potentially reflecting T-cell recognition of tumor cells with IFN-γ secretion in an inflamed tumor microenvironment \[[@CR27]\]. In breast cancer, high *PD-L1*-mRNA levels were associated with response to chemotherapy and high *PD-L1-*mRNA tissue levels have been suggested as a marker for anti-tumor immune response \[[@CR28], [@CR29]\]. Melanoma patients who were non-responsive towards immune checkpoint therapy targeting CTLA-4 displayed defective IFN-γ signaling \[[@CR30]\]. Along this line, loss of function mutations in JAK1/JAK2 that prevent IFN-γ signaling were associated with primary \[[@CR31]\] and acquired resistance \[[@CR32]\] towards PD-1/PD-L1-based immune checkpoint blockade therapy. Conversely, tandem amplification of PD-L1/PD-L2 and JAK2, causing enhanced IFN-γ signaling, was associated with high responsiveness towards immune checkpoint blockade in Hodgkin's lymphoma \[[@CR33], [@CR34]\].

Based on immunohistological detection, PD-L1 protein expression has been investigated as a predictive or prognostic biomarker in various malignancies \[[@CR35]\]. The results from these studies differed from the associations of *PD-L1-*mRNA tissue homogenate levels with disease outcome: Contrary to high *PD-L1-*mRNA levels, a high PD-L1 immune histology score was associated with short survival in different malignancies, including RCC, independent of therapy \[[@CR36]\]. In melanoma, a high PD-L1 protein score was associated with shorter survival \[[@CR37]\]. In particular, a high PD-L1 score, considering PD-L1 in cancer cells or macrophages, predicted both worse outcome and, in a mouse model, the knockout of PD-L1 or of IFN-γ signaling by STAT1-knockdown in tumor cells prolonged survival \[[@CR37]\]. Furthermore, in RCC, a high PD-L1 protein score was predictive of poor outcome in patients who received anti-angiogenic TKI treatment with sunitinib or pazopanib (COMPARZ trial) \[[@CR38]\]. In contrast, patients with tumors that displayed a high T-effector gene signature score, correlating with a high PD-L1 protein level in immune cells within RCC tumor tissues, were suggested to benefit from combined anti-PD-L1 and antiangiogenic therapy \[[@CR36]\].

The contrary associations between patient survival and PD-L1 immunoscore (high PD-L1 protein/short survival) versus *PD-L1-*mRNA (low *PD-L1-*mRNA/short survival) may seem implausible. However, protein levels and mRNA levels may not be concordant since numerous post-transcriptional regulation mechanisms exist that have relevance for PD-L1. These include signaling proteins such as PBRM1, CMTM4, CMTM6, Ras, MEK, and ERK, which regulate PD-L1 post-transcriptionally \[[@CR15], [@CR16], [@CR39]\]. In addition, micro-RNAs may contribute to the regulation. In particular, mir-155 and mir-513 represent targets of IFN-γ signaling with critical impact on PD-L1 mRNA and protein levels \[[@CR40]--[@CR42]\]. Due to the considerable post-transcriptional influence on PD-L1 protein, the *PD-L1*-mRNA level may more closely reflect the PD-L1 induction that occurs as a consequence of active tumor recognition by T cells. Nonetheless, mRNA detection of tissue homogenates has the limitation that it is not possible to discriminate between expression by cancer cells, immune cells, or other cells of the tissue environment. Therefore, histologic RNA detection by in situ hybridization combined with immune histology in order to identify the cellular context may be a technical advance to improving our understanding of the PD-L1/PD-1 biology in tumor environments and its relation to patient outcome and therapy response. Prospectively, GSEA performed with gene sets for certain cell types and signaling pathways may retrieve deeper information about the tissue biology from RNA-data sets.

Independent of the detection method, it is the interconnected biology of PD-L1 and T-cell activity, the latter measured as IFN-γ response, which indicates the immune-reactive state of the tissue. This can be identified as a correlation of PD-L1 (protein or mRNA) with IFN-γ signaling, or as a spatial co-positioning of PD-L1 protein with T cells in tumor tissues by immune histology. If such a scenario is observed, there is strong evidence of IFN-γ-regulated PD-L1 likely through immune recognition of the tumor cells, which might be reflected in longer survival.

Conclusions {#Sec16}
===========

In summary, we demonstrated that RCC cells differ with respect to PD-L1 regulation by IFN-γ-signaling. In ccRCC cells, IFN-γ signaling is predominantly intact with IFN-γ-dependent PD-L1 induction. In pRCC, IFN-γ responsiveness is attenuated with PD-L1 expression independent of IFN-γ. In IFN-γ-responsive tumors such as ccRCC and SKCM, high *PD-L1-*mRNA levels are associated with prolonged survival of patients, but not in pRCC patients. We suggest that *PD-L1-*mRNA tumor tissue level correlated to IFN-γ signaling as a marker of favorable prognosis and response to PD-1/PD-1 checkpoint blockade for those tumors that do not constitutively express PD-L1.
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